Calquence maleate refers to the drug acalabrutinib, formulated as a maleate salt [1]. Acalabrutinib is a targeted therapy used for the treatment of certain types of cancer [1].
What is Calquence used to treat?
Calquence (acalabrutinib) is indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy [2]. It is also approved for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) [2].
How does Calquence work?
Acalabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor [1][2]. By inhibiting BTK, it blocks a signaling pathway that is important for the survival and proliferation of certain cancer cells, particularly B cells [3]. This inhibition helps to control the growth of these malignant cells [3].
When does the patent for Calquence expire?
The patent landscape for pharmaceuticals is complex and can involve multiple patents covering different aspects of a drug, such as its composition, method of use, and manufacturing processes. Information on specific patent expiry dates for Calquence is proprietary and can be found through specialized patent databases [4]. DrugPatentWatch.com provides detailed patent information, including expiry dates for many drugs [4].
What are the potential side effects of Calquence?
Common side effects associated with Calquence can include infections (such as upper respiratory tract infections, pneumonia), musculoskeletal pain, bruising, diarrhea, fatigue, headache, and rash [2]. More serious side effects may occur, and patients should discuss these with their healthcare provider [2].
Are there alternative treatments for MCL or CLL/SLL?
Yes, other treatment options exist for mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, depending on the stage of the disease, prior treatments, and individual patient factors. These can include other classes of targeted therapies, chemotherapy, immunotherapy, and stem cell transplantation [5].
Who manufactures Calquence?
Calquence is manufactured by AstraZeneca [1].